New anti-virulence drugs against S. aureus

Short description

In this project, the scientists have developed a monoclonal antibody directed against a resistance protein that is crucial for the virulence, i.e. infectious effect, of Staphylococcus aureus. The monoclonal antibody can restore the body's own defence and thus make the bacteria vulnerable to antibiotics.

In recent years, multidrug-resistant organisms (MDRO) have spread, particularly in clinics worldwide. Research into the control and treatment of these infections poses a multifaceted challenge: One goal is to reduce the inappropriate use of antibiotics, e.g. through antibiotic stewardship. It is also important to reduce the transmission of multi-resistant bacteria through improved hygiene measures and to reduce the selection pressure for the development of resistances by developing new and sustainable antibiotics. However, the existing studies are not sufficient to optimize hygiene measures and therapy guidelines and new anti-infectives such as anti-virulence agents are only at the experimental stage.

The development of new broad-spectrum antibiotics is imperative, but will only solve the problems temporarily: A strong selection pressure, the disturbance of the microflora and the predisposition for Clostridium difficile infections counteract this. In order to develop more sustainable antibiotics, the concept of anti-virulence agents is being pursued. New inhibitors directed against toxins, secretion systems or other decisive virulence factors are currently being under research and are about to enter preclinical testing.